Thomas Habermann, MD, discusses the unmet clinical needs which still exist for patients with diffuse large B-cell lymphoma.
Thomas Habermann, MD, a hematologist with the Mayo Clinic, discusses the unmet clinical needs which still exist for patients with diffuse large B-cell lymphoma (DLBCL).
Many know the combination of rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) to be a highly effective therapy for patients with DLBCL. However, since its development, not much has been done in order to improve on the combination.
Because of this, experts, including Habermann, are focusing their research on the addition of polatuzumab vedotin (Polivy) to the combination in order to potentially improve outcomes for these patients. Their goal is to be able to cure 100% of those diagnosed with DLBCL.
Transcription:
0:08 | In DLBCL the unmet need is to cure 100% of patients, and until we get there, we can't be satisfied. If you take R-CHOP alone in advanced disease, beyond the limited stage up front, if you take all comers, we can cure about 65% of patients. If you took other tumors and looked at it, well that's pretty good, but that really isn't good enough. If you take the data that we presented on limited stage disease, we still have issues.
0:48 | We've come a long way in this disease, in both limited stage disease and advanced disease, but in limited stage disease there is a long way to go. We've decreased the toxicity and exposures and decreased the risk of developing secondary malignancies with less chemotherapy potentially, we've also decreased the risk of secondary malignancies as a result of radiation therapy. Now radiation therapy approaches have been also changing with proton beams and other approaches. It'll be very fascinating to see the whole evolution of where things are going to end up.
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More
Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL
April 1st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the long-term results with loncastuximab in patients with diffuse large B-cell lymphoma and how this drug fared in the real-world setting in the second article of a 2-part series.
Read More
Fitting Loncastuximab Into the Current Landscape of R/R DLBCL
March 21st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.
Read More